Quest Diagnostics (DGX) SVP exercises options, sells 5,662 shares under 10b5-1 plan

Rhea-AI Filing Summary

Quest Diagnostics executive Patrick Plewman reported multiple stock transactions involving DGX shares. On January 28, 2026, he acquired 48 shares of common stock at $183.512 per share through a dividend reinvestment plan administered by his broker, bringing direct ownership to 15,381 shares.

On February 10, 2026, he exercised a non-qualified stock option for 5,662 shares of common stock at an exercise price of $121.805 per share and immediately sold 5,662 shares of common stock at $204 per share in an open-market transaction. After these transactions, he directly owned 15,381 shares of Quest Diagnostics common stock. The filing notes that the option exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan.

Insights

Equity compensation and insider-trading analyst

Routine option exercise and sale under a 10b5-1 plan; neutral impact.

SVP for Diagnostic Services Patrick Plewman exercised a non-qualified stock option for 5,662 DGX shares at $121.805 and sold the same number at $204 on February 10, 2026. This is a standard monetization of equity compensation.

The filing specifies the transactions occurred under a pre-established Rule 10b5-1 sales plan, indicating they were pre-arranged rather than opportunistic. He also acquired 48 shares via a dividend reinvestment plan on January 28, 2026, and reported it earlier than required.

After the reported transactions, Plewman directly holds 15,381 shares of Quest Diagnostics common stock. This appears to be a routine insider activity rather than a signal of a major change in outlook, so the overall informational impact is limited.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A	V	48(1)	A	$183.512	15,381	D
Common Stock	02/10/2026		M(2)		5,662	A	$121.805	21,043	D
Common Stock	02/10/2026		S(2)		5,662	D	$204	15,381	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualifed Stock Option (right to buy)	$121.805	02/10/2026		M(2)			5,662	(3)	02/17/2031	Common Stock	5,662	$121.805	0	D

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

2. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

3. The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Patrick Plewman report for Quest Diagnostics (DGX)?

Patrick Plewman reported exercising a non-qualified stock option for 5,662 DGX shares at $121.805 and selling 5,662 shares at $204 on February 10, 2026. He also acquired 48 shares via a dividend reinvestment plan on January 28, 2026.

How many Quest Diagnostics (DGX) shares does Patrick Plewman own after these transactions?

After the reported transactions, Patrick Plewman directly owns 15,381 shares of Quest Diagnostics common stock. This figure reflects his holdings following the January 28, 2026 dividend reinvestment acquisition and the February 10, 2026 option exercise and related sale.

Were Patrick Plewman’s Quest Diagnostics (DGX) stock sales pre-planned?

Yes. The Form 4 states that the February 10, 2026 option exercise and related sale were executed under a Rule 10b5-1 sales plan. Such plans are pre-arranged trading programs that schedule transactions in advance to help manage potential insider trading concerns.

What was the price of Patrick Plewman’s Quest Diagnostics (DGX) option exercise and share sale?

Patrick Plewman exercised a non-qualified stock option at an exercise price of $121.805 per DGX share and sold 5,662 common shares at $204 per share on February 10, 2026. These prices are specifically disclosed in the Form 4 filing tables.

What is the nature of the 48 Quest Diagnostics (DGX) shares acquired by Patrick Plewman?

The 48 DGX shares acquired on January 28, 2026 were obtained through a dividend reinvestment plan administered by his broker. The filing notes these shares were eligible for deferred reporting on Form 5, but he chose to disclose them early on this Form 4.

What derivative security did Patrick Plewman exercise related to Quest Diagnostics (DGX)?

He exercised a non-qualified stock option, described as a right to buy Quest Diagnostics common stock, covering 5,662 shares at an exercise price of $121.805. After this exercise on February 10, 2026, he no longer held any of these derivative securities.